tiprankstipranks
Advertisement
Advertisement
Lyra Therapeutics Faces Nasdaq Delisting After Becoming Shell
PremiumCompany AnnouncementsLyra Therapeutics Faces Nasdaq Delisting After Becoming Shell
3M ago
Lyra Therapeutics common stock to be delisted by Nasdaq
Premium
The Fly
Lyra Therapeutics common stock to be delisted by Nasdaq
3M ago
One new option listing and  option delistings on January 20th
Premium
The Fly
One new option listing and option delistings on January 20th
4M ago
Cautious Hold Rating for Lyra Therapeutics Amid Strategic Focus and Financial Challenges
PremiumRatingsCautious Hold Rating for Lyra Therapeutics Amid Strategic Focus and Financial Challenges
6M ago
Lyra Therapeutics Faces Financial Challenges Amid Clinical Setbacks
Premium
Company Announcements
Lyra Therapeutics Faces Financial Challenges Amid Clinical Setbacks
6M ago
Lyra Therapeutics reports Q3 EPS ($3.38), consensus ($4.07)
Premium
The Fly
Lyra Therapeutics reports Q3 EPS ($3.38), consensus ($4.07)
6M ago
Cautious Hold Rating on Lyra Therapeutics Amid Uncertainty in LYR-210’s Development and Approval Prospects
PremiumRatingsCautious Hold Rating on Lyra Therapeutics Amid Uncertainty in LYR-210’s Development and Approval Prospects
9M ago
Lyra Therapeutics Faces Manufacturing and Staffing Challenges Amid LYR-210 Production Shift
Premium
Company Announcements
Lyra Therapeutics Faces Manufacturing and Staffing Challenges Amid LYR-210 Production Shift
9M ago
Lyra Therapeutics Reports Q2 2025 Financial Results
Premium
Company Announcements
Lyra Therapeutics Reports Q2 2025 Financial Results
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100